<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04151459</url>
  </required_header>
  <id_info>
    <org_study_id>[2018]048</org_study_id>
    <nct_id>NCT04151459</nct_id>
  </id_info>
  <brief_title>Effect of Metabolic Surgery on Live Birth Rate of Offspring in Obesity Polycystic Ovarian Syndrome Patients</brief_title>
  <official_title>Effect of Laparoscopic Sleeve Gastrectomy (LSG) on Live Birth Rate of Offspring in Polycystic Ovarian Syndrome (PCOS) Patients With Severely Obese</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a experimental study, which subjects are obese PCOS patients requiring LSG surgery.
      Aim to investigate the effects of LSG surgery in PCOS patients whether increases the live
      birth rate of the offspring.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators designed a single center small sample exploratory study to clear the
      therapeutic effects of laparoscopic sleeve gastrectomy on live birth rate improvements of
      overweight/obese PCOS patients. The investigators plan to enroll 18 patients. Inclusion
      criteria: 1) Patients who are aged from 18 to 45, not menopause;2) have PCOS which is
      diagnosed according to 2003 Rotterdam criteria; 3) have been treated with behavioral and
      drugs intervention for 3 months but are ineffective; 4) have steady or steady weight gain
      over 5 years, BMI&gt;35kg/m2, or BMI&gt;30kg/m2 with one of the metabolic disorders such as
      impaired glucose tolerance, cardiovascular disease, fatty liver, lipid metabolism disorders,
      sleep apnea syndrome.

      Patients with serious complications (cardiovascular events and recent significant liver,
      kidney or lung disease within 3 months); high blood pressure (&gt;160/100mmHg); active
      infection; secondary diabetes; pregnancy; alcohol abuse; surgical contraindications are
      excluded.

      Then the investigators plan to perform laparoscopic sleeve gastrectomy . Before and after the
      intervention, the blood samples would be collected to detect blood glucose, insulin, lipid
      profile, sex hormones, blood chemistry for liver and kidney function, hsCRP etc., as well as
      the anthropometric measurement and image examinations. All patients are followed up every 3
      months until the end of the program. All patients receive MRI plain scan of upper and lower
      abdomen, oral glucose tolerance test (OGTT) and insulin, C-peptide releasing test again every
      6 months after the operation. One year after the operation, patients would be evaluated
      whether they are suitable for pregnancy preparation and record the pregnancy mode. After
      pregnancy, various indicators would be closely monitored, including maternal vitamin and
      trace element levels.The birth of children and the live birth rate would be recorded.

      The investigators will compare the data and finally identify the treatment effect of
      laparoscopic sleeve gastrectomy on overweight/obese PCOS patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2019</start_date>
  <completion_date type="Anticipated">January 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of metabolic surgery on live birth rate of offspring in obesity PCOS patients.</measure>
    <time_frame>up to 3 years</time_frame>
    <description>To record the offspring production and live birth rate of obesity PCOS patients after metabolic surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of metabolic surgery on ovulation rate and pregnancy rate of PCOS patients</measure>
    <time_frame>up to 3 years</time_frame>
    <description>To compare the ovulation rate and pregnancy of obesity PCOS patient with metabolic surgery or not</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of metabolic surgery on intestinal flora of PCOS patients and progeny.</measure>
    <time_frame>up to 3 years</time_frame>
    <description>To compare the intestinal flora of PCOS patients after metabolic surgery</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Severe Obesity</condition>
  <condition>Laparoscopic Sleeve Gastrectomy</condition>
  <arm_group>
    <arm_group_label>Laparoscopic sleeve gastrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laparoscopic sleeve gastrectomy on severe obesity PCOS patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Use Metformin for 3 months to treat PCOS</description>
    <arm_group_label>Laparoscopic sleeve gastrectomy</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - aged from 18 to 45, not menopause have PCOS which is diagnosed according to 2003
        Rotterdam criteria have been treated with behavioral and drugs intervention for 3 months
        but are ineffective have steady or steady weight gain over 5 years, BMI&gt;35kg/m2, or
        BMI&gt;30kg/m2 with one of the metabolic disorders such as impaired glucose tolerance,
        cardiovascular disease, fatty liver, lipid metabolism disorders, sleep apnea syndrome

        Exclusion Criteria:

        - Except for serious complications (cardiovascular events and recent significant liver,
        kidney or lung disease within 3 months) high blood pressure (&gt;160/100mmHg) active infection
        secondary diabetes pregnancy alcohol abuse surgical contraindications
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tao Tao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>RenJi Hospital Department of Endocrinology and Metabolism</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tao Tao, MD</last_name>
    <phone>+86-13817701776</phone>
    <email>taotaozhen@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuchen Zhu, Master</last_name>
    <phone>+86-13817946105</phone>
    <email>zhuyuchen_cc@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Tao, Doctor</last_name>
      <phone>+86-13817701776</phone>
      <email>taotaozhen@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Li R, Zhang Q, Yang D, Li S, Lu S, Wu X, Wei Z, Song X, Wang X, Fu S, Lin J, Zhu Y, Jiang Y, Feng HL, Qiao J. Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Hum Reprod. 2013 Sep;28(9):2562-9. doi: 10.1093/humrep/det262. Epub 2013 Jun 27.</citation>
    <PMID>23814096</PMID>
  </reference>
  <reference>
    <citation>Jarrett BY, Lujan ME. Impact of hypocaloric dietary intervention on ovulation in obese women with PCOS. Reproduction. 2016 Oct 31. pii: REP-16-0385. [Epub ahead of print]</citation>
    <PMID>27799625</PMID>
  </reference>
  <reference>
    <citation>Behboudi-Gandevani S, Ramezani Tehrani F, Rostami Dovom M, Farahmand M, Bahri Khomami M, Noroozzadeh M, Kabir A, Azizi F. Insulin resistance in obesity and polycystic ovary syndrome: systematic review and meta-analysis of observational studies. Gynecol Endocrinol. 2016;32(5):343-53. doi: 10.3109/09513590.2015.1117069. Epub 2016 Jan 6. Review.</citation>
    <PMID>27052492</PMID>
  </reference>
  <reference>
    <citation>Skubleny D, Switzer NJ, Gill RS, Dykstra M, Shi X, Sagle MA, de Gara C, Birch DW, Karmali S. The Impact of Bariatric Surgery on Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis. Obes Surg. 2016 Jan;26(1):169-76. doi: 10.1007/s11695-015-1902-5. Review.</citation>
    <PMID>26431698</PMID>
  </reference>
  <reference>
    <citation>Niu Z, Lin N, Gu R, Sun Y, Feng Y. Associations between insulin resistance, free fatty acids, and oocyte quality in polycystic ovary syndrome during in vitro fertilization. J Clin Endocrinol Metab. 2014 Nov;99(11):E2269-76. doi: 10.1210/jc.2013-3942. Epub 2014 Apr 2.</citation>
    <PMID>24694334</PMID>
  </reference>
  <reference>
    <citation>Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, Mullany EC, Biryukov S, Abbafati C, Abera SF, Abraham JP, Abu-Rmeileh NM, Achoki T, AlBuhairan FS, Alemu ZA, Alfonso R, Ali MK, Ali R, Guzman NA, Ammar W, Anwari P, Banerjee A, Barquera S, Basu S, Bennett DA, Bhutta Z, Blore J, Cabral N, Nonato IC, Chang JC, Chowdhury R, Courville KJ, Criqui MH, Cundiff DK, Dabhadkar KC, Dandona L, Davis A, Dayama A, Dharmaratne SD, Ding EL, Durrani AM, Esteghamati A, Farzadfar F, Fay DF, Feigin VL, Flaxman A, Forouzanfar MH, Goto A, Green MA, Gupta R, Hafezi-Nejad N, Hankey GJ, Harewood HC, Havmoeller R, Hay S, Hernandez L, Husseini A, Idrisov BT, Ikeda N, Islami F, Jahangir E, Jassal SK, Jee SH, Jeffreys M, Jonas JB, Kabagambe EK, Khalifa SE, Kengne AP, Khader YS, Khang YH, Kim D, Kimokoti RW, Kinge JM, Kokubo Y, Kosen S, Kwan G, Lai T, Leinsalu M, Li Y, Liang X, Liu S, Logroscino G, Lotufo PA, Lu Y, Ma J, Mainoo NK, Mensah GA, Merriman TR, Mokdad AH, Moschandreas J, Naghavi M, Naheed A, Nand D, Narayan KM, Nelson EL, Neuhouser ML, Nisar MI, Ohkubo T, Oti SO, Pedroza A, Prabhakaran D, Roy N, Sampson U, Seo H, Sepanlou SG, Shibuya K, Shiri R, Shiue I, Singh GM, Singh JA, Skirbekk V, Stapelberg NJ, Sturua L, Sykes BL, Tobias M, Tran BX, Trasande L, Toyoshima H, van de Vijver S, Vasankari TJ, Veerman JL, Velasquez-Melendez G, Vlassov VV, Vollset SE, Vos T, Wang C, Wang X, Weiderpass E, Werdecker A, Wright JL, Yang YC, Yatsuya H, Yoon J, Yoon SJ, Zhao Y, Zhou M, Zhu S, Lopez AD, Murray CJ, Gakidou E. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014 Aug 30;384(9945):766-81. doi: 10.1016/S0140-6736(14)60460-8. Epub 2014 May 29. Erratum in: Lancet. 2014 Aug 30;384(9945):746.</citation>
    <PMID>24880830</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>November 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>November 2, 2019</last_update_submitted>
  <last_update_submitted_qc>November 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <keyword>Severe Obesity</keyword>
  <keyword>Laparoscopic Sleeve Gastrectomy</keyword>
  <keyword>Live Birth Rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

